Related Experiment Videos

Is dyslipidaemia important if we control glycaemia?

Guntram Schernthaner1

  • 1Department of Medicine I, Rudolfstiftung Hospital Vienna, Juchgasse 25, A-1030 Vienna, Austria. guntram.schernthaner@wienkav.at

Atherosclerosis. Supplements
|August 2, 2005
PubMed

Insights

People with type 2 diabetes face high cardiovascular risk. Multifactorial interventions, including lipid normalization, are key, but novel combination therapies are needed to improve outcomes.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Syndrome

Background:

  • Type 2 diabetes significantly increases morbidity and mortality from cardiovascular disease (CVD).
  • Patients with type 2 diabetes exhibit a cluster of coronary heart disease (CHD) risk factors, including dyslipidemia.
  • Standard intensive glucose-lowering interventions have failed to eliminate elevated cardiovascular risk.

Purpose of the Study:

  • To evaluate the effectiveness of multifactorial interventions in reducing cardiovascular risk in type 2 diabetes.
  • To explore strategies for improving high-density lipoprotein cholesterol (HDL-C) levels in this population.
  • To identify safe and effective combination lipid-lowering therapies for type 2 diabetes and metabolic syndrome.

Main Methods:

  • Review of studies on multifactorial interventions for cardiovascular risk reduction in type 2 diabetes.
  • Analysis of the impact of statins and other lipid-modifying agents on CHD risk.
  • Examination of the role of HDL-C and strategies to increase it.

Main Results:

  • Multifactorial interventions, including statin therapy for lipid normalization, show greater efficacy in reducing CHD than single-factor approaches.
  • Risk reduction in type 2 diabetes patients often mirrors that in non-diabetic individuals, despite higher baseline risk.
  • Statins minimally improve HDL-C; additional interventions are needed, but combining fibrates with statins carries risks.

Conclusions:

  • Multifactorial interventions are superior for managing cardiovascular risk in type 2 diabetes.
  • Targeting HDL-C is crucial for further reducing cardiovascular morbidity and mortality.
  • Novel combination lipid-normalizing therapies are required for patients with type 2 diabetes or metabolic syndrome, avoiding risks associated with current combinations.

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...